177 related articles for article (PubMed ID: 32901879)
41. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.
Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O
Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808
[TBL] [Abstract][Full Text] [Related]
42. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
43. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
[TBL] [Abstract][Full Text] [Related]
45. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
46. Differentially expressed microRNA-218 modulates the viability of renal cell carcinoma by regulating BCL9.
Wang J; Ying Y; Bo S; Li G; Yuan F
Mol Med Rep; 2016 Aug; 14(2):1829-34. PubMed ID: 27314976
[TBL] [Abstract][Full Text] [Related]
47. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
[TBL] [Abstract][Full Text] [Related]
48. Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma.
Di J; Gao K; Qu D; Yang J; Zheng J
Tumour Biol; 2017 Jul; 39(7):1010428317701653. PubMed ID: 28691643
[TBL] [Abstract][Full Text] [Related]
49. HBXIP accelerates glycolysis and promotes cancer angiogenesis via AKT/mTOR pathway in bladder cancer.
Liu X; Li H; Che N; Zheng Y; Fan W; Li M; Li X; Xuan Y
Exp Mol Pathol; 2021 Aug; 121():104665. PubMed ID: 34216584
[TBL] [Abstract][Full Text] [Related]
50. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.
Damiano V; Rosa R; Formisano L; Nappi L; Gelardi T; Marciano R; Cozzolino I; Troncone G; Agrawal S; Veneziani BM; De Placido S; Bianco R; Tortora G
Br J Cancer; 2013 Apr; 108(8):1616-23. PubMed ID: 23571736
[TBL] [Abstract][Full Text] [Related]
51. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
53. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.
Ding C; Luo J; Fan X; Li L; Li S; Wen K; Feng J; Wu G
J Exp Clin Cancer Res; 2017 Apr; 36(1):56. PubMed ID: 28420432
[TBL] [Abstract][Full Text] [Related]
54. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
55. MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway.
Fu JH; Yang S; Nan CJ; Zhou CC; Lu DQ; Li S; Mu HQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):351-357. PubMed ID: 29424922
[TBL] [Abstract][Full Text] [Related]
56. Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis.
Xu HF; Chen L; Liu XD; Zhan YH; Zhang HH; Li Q; Wu B
Asian Pac J Cancer Prev; 2014; 15(7):3045-50. PubMed ID: 24815445
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-122 promotes proliferation, invasion and migration of renal cell carcinoma cells through the PI3K/Akt signaling pathway.
Lian JH; Wang WH; Wang JQ; Zhang YH; Li Y
Asian Pac J Cancer Prev; 2013; 14(9):5017-21. PubMed ID: 24175769
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-363 inhibits angiogenesis, proliferation, invasion, and migration of renal cell carcinoma via inactivation of the Janus tyrosine kinases 2-signal transducers and activators of transcription 3 axis by suppressing growth hormone receptor gene.
Zhu J; Zhu DQ; Zhang Y; Liu QM; Wang PC; Li HZ; Ma X; Zhang X
J Cell Physiol; 2019 Mar; 234(3):2581-2592. PubMed ID: 30229899
[TBL] [Abstract][Full Text] [Related]
59. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
60. Tuftelin 1 (TUFT1) Promotes the Proliferation and Migration of Renal Cell Carcinoma
Lin H; Zeng W; Lei Y; Chen D; Nie Z
Pathol Oncol Res; 2021; 27():640936. PubMed ID: 34257606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
